Risk factors

Hurricane exposure in South Florida dominates the company's operations and insurance risks.

Citius Oncology is entirely dependent on the commercial success and funding of its sole approved product, LYMPHIR, which gained FDA approval in August 2024. The company faces significant financial pressures, including a history of net losses, the need for substantial additional capital, and milestone obligations totaling millions to Eisai and Dr. Reddy's. Operations rely heavily on third-party manufacturers, outsourced commercial partners, and shared services with Citius Pharma, which owns approximately 92.3% of its common stock.

Citius Pharmaceuticals faces going concern doubts and requires immediate funding to support operations and launch LYMPHIR. The company relies heavily on third parties for manufacturing, clinical trials, and commercialization of its product candidates. Future profitability depends entirely on regulatory approvals and market acceptance of unproven pipeline assets like LYMPHIR and Mino-Lok.

This is an initial filing with no prior year comparison.

Forward Industries faces recurring net losses, including $1,951,000 in Fiscal 2024, raising going concern doubts. High customer concentration in diabetic products accounts for 77% of OEM distribution revenue. Operations depend heavily on exclusive sourcing agent Forward China, to which the company owes significant accounts payable and a $600,000 note.

Supermarket operations depend heavily on labor supply, fuel prices, and supply chain efficiency.

The company relies heavily on the success of its sole approved product candidate, ONS-5010/LYTENAVA, facing substantial cash burn and ongoing capital needs. Clinical development hurdles, intellectual property protections, and heavy dependence on single-source suppliers dominate the operational risk profile.

Bridgeline Digital faces persistent net losses, accumulating $92 million in deficits alongside ongoing revenue and liquidity pressures.

Eureka Acquisition Corp completed its 5,000,000 unit IPO on July 3, 2024, raising $50,000,000 gross proceeds. The company holds $57,500,000 in a trust account and has no active operations or revenues yet.

As a blank check company, IB Acquisition Corp faces core risks around finding a business combination target, potential conflicts of interest with I-Bankers and management, and public stockholder redemption rights.

Mobix Labs faces a going concern doubt with only ninety days of liquidity and an accumulated deficit of $104.5 million. Operations suffer from material weaknesses in internal controls requiring costly remediation. The company relies heavily on third-party offshore manufacturers and a limited number of customers.

Customer concentration creates significant revenue risk with three customers accounting for 41 percent of sales. Total backlog stands at $114.4 million but remains subject to cancellations. Goodwill of $3.5 million risks impairment against total assets of $104.6 million.